Silence=Death graphic
People Who Use Drugs

Message on Opioids From HIV Docs to Colleagues Is Clear: Get Training, Prescribe Buprenorphine, Save Lives

Although IDWeek is over, many conference presenters sought to impart one lasting message to their colleagues: Start treating your patients with opioid use disorder and get political about it.

By Sony Salzman
Promo Image

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

By Sony Salzman
Man holdin his head

Lessons for Infectious Disease Doctors: Treating HIV, Pain, and Mental Illness

A staggering 60% of patients with HIV experience chronic pain compared with only 11% of the general population, according to Robert Bruce, M.D., M.A., M.Sc., who presented the latest research on pain and HIV at IDWeek 2018.

By Sony Salzman
Allison Glaser, M.D.

New York City's Hotline for HIV Exposure a Success, Study Finds

A dial-in hotline program in New York City has helped qualified patients access post-exposure prophylaxis (PEP) at their local pharmacies, raising the possibility that remote screening methods could be an important way to bolster PEP use.

By Sony Salzman
Anisha Apte, B.S.

New Study From Georgia Sheds Light on Kaposi Sarcoma in Women With HIV

The skin cancer Kaposi Sarcoma (KS) is an HIV-related condition that primarily affects men, but a new cases series presented at IDWeek 2018 in San Francisco highlights the importance of studying women with KS.

By Sony Salzman
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

By Barbara Jungwirth
Jodian Pinkney, M.D.

Jamaican Study of Serodiscordant Couples Highlights Challenges of PrEP Awareness

A poster presented at the annual IDWeek conference in San Francisco illustrated the lag between the World Health Organization's recommendations and PrEP uptake in an urban setting in Jamaica.

By Sony Salzman
'Mini'-Really Rapid Review -- IDWeek 2018, San Francisco Img

'Mini'-Really Rapid Review -- IDWeek 2018, San Francisco

Paul Sax, M.D., provides a rundown of the research that caught his attention at this year's IDWeek conference.

By Paul E. Sax, M.D.
Donna Futterman, M.D. and Rachel L. Epstein, M.D., M.A.
People Who Use Drugs

Too Few Teens and Youth Adults Using Opioids Are Screened for Hepatitis C and HIV, New Study Finds

Despite their increased risk, only one-third of adolescents and young adults with known opioid use disorder were screened for hepatitis C, according to a study released at the IDWeek conference in San Francisco.

By Kenyon Farrow
Truvada pill and glass of water

First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

A poster presentation at IDWeek in San Francisco revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). But is it of concern?

By Damon L. Jacobs, L.M.F.T.